Comparison of Gamma Nail Versus Dynamic Hip Screw for the Treatment of Unstable Intertrochanteric Fractures
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01173744|
Recruitment Status : Unknown
Verified July 2010 by Wolfson Medical Center.
Recruitment status was: Recruiting
First Posted : August 2, 2010
Last Update Posted : June 17, 2011
The objective of the study is to examine the treatment of unstable Intertrochanteric fractures with the short Gamma nail, compared to the use of the dynamic hip screw (DHS).
This is a prospective study. Sixty patients with unstable Intertrochanteric fractures will be randomized to be treated using either Gamma nail or DHS. The patients will be followed for 12 months. The primary endpoint is the clinical outcome as measured by the Merle d'Aubigne and Postelhip score.
|Condition or disease||Intervention/treatment||Phase|
|Intertrochanteric Femoral Fractures||Device: Gamma-3 Nail Device: DHS||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Study Start Date :||July 2010|
|Estimated Primary Completion Date :||July 2012|
|Estimated Study Completion Date :||July 2012|
|Experimental: Gamma-3 Nail||
Device: Gamma-3 Nail
Gamma-3 Nail (stryker)
|Active Comparator: DHS||
- Clinical outcome as measured by the Merle d'Aubigne and Postel hip score [ Time Frame: 1 year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01173744
|Contact: Dror Lakstein, MDfirstname.lastname@example.org|
|E. WOlfson medical center||Recruiting|
|Holon, Israel, 58100|
|Contact: Dror Lakstein, MD ++972-3-5028383 email@example.com|
|Principal Investigator: Dror Lakstein, MD|